p stat3 (Bioss)
Bioss is a verified supplier 
Bioss manufactures this product 
94
Structured Review
Bioss
p stat3
P Stat3, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 50 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stat3+(tyr705)+polyclonal+antibody/STAT3+(Tyr705)+Polyclonal+Antibody/pmc12865882-92-50-55
Average 94 stars, based on 50 article reviews
P Stat3, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 50 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stat3+(tyr705)+polyclonal+antibody/STAT3+(Tyr705)+Polyclonal+Antibody/pmc12865882-92-50-55
Average 94 stars, based on 50 article reviews
p stat3 - by Bioz Stars,
2026-09
94/100 stars
Images
1) Product Images from "Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway"
Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway
Journal: Molecular Medicine Reports
doi: 10.3892/mmr.2026.13805
Figure Legend Snippet: Naringin inhibits JAK2/STAT3 signaling and restores tight junction proteins in dextran sulfate sodium-induced colitis. (A) Representative western blotting images of p-JAK2, JAK2, p-STAT3, STAT3, IL-6, occludin, ZO-1 and β-actin expression in colon tissues. Densitometric semi-quantification of the relative protein expression levels of (B) p-JAK2/β-actin, (C) JAK2/β-actin, (D) p-JAK2/JAK2, (E) p-STAT3/β-actin, (F) STAT3/β-actin, (G) p-STAT3/STAT3, (H) IL-6/β-actin, (I) occludin/β-actin and (J) ZO-1/β-actin. Data are presented as mean ± SEM. n=3. *P<0.05 and **P<0.01 vs. control group; # P<0.05 and ## P<0.01 vs. normal group. One-way ANOVA followed by Tukey's post-hoc test was applied. N, normal group; C, control group; Nar, naringin group; Mes, mesalazine group; p-, phosphorylated; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; IL-6, ZO-1, zona occludens-1.
Techniques Used: Western Blot, Expressing, Control
Figure Legend Snippet: Naringin reverses IL-6-induced ZO-1 and occludin impairment in a STAT3-dependent manner. (A) Immunofluorescence staining for ZO-1 (blue) and occludin (green); nuclei were stained with DAPI (cyan). Merged shows the merged images of DAPI and respective protein staining. Quantitative analysis of relative (B) ZO-1 and (C) occludin protein expression. (n=3). Data are presented as mean ± SEM. *P<0.05 and **P<0.01 vs. IL-6 group; ## P<0.01 vs. normal group. One-way ANOVA followed by Tukey's post-hoc test was applied. ZO-1, zona occludens-1; N, normal group; Nar, naringin; STAT3, signal transducer and activator of transcription 3; si, small interfering RNA; NC, negative control.
Techniques Used: Immunofluorescence, Staining, Expressing, Small Interfering RNA, Negative Control
Figure Legend Snippet: Naringin suppresses JAK2/STAT3 activation in IL-6-stimulated Caco-2 cells with STAT3 silencing. (A) Western blot analysis of p-JAK2, JAK2, p-STAT3, STAT3, occludin and ZO-1 in Caco-2 cells under indicated treatments. (B) Validation of STAT3 knockdown efficiency: Relative STAT3 expression in cells transfected with siSTAT3 vs. siNC. ## P<0.01 vs. siNC. Densitometric semi-quantification of relative protein expression levels of (C) p-JAK2/β-actin, (D) JAK2/β-actin, (E) p-JAK2/JAK2, (F) p-STAT3/β-actin, (G) STAT3/β-actin, (H) p-STAT3/ STAT3, (I) occludin/β-actin, (J) ZO-1/β-actin. Data are presented as mean ± SEM. n=3. *P<0.05 and **P<0.01 vs. IL-6 group; ## P<0.01 vs. normal group; Δ P<0.05 and ΔΔ P<0.01 IL-6 + Nar group vs. IL-6 + Nar + siSTAT3 group. One-way ANOVA followed by Tukey's post-hoc test was applied. N, normal group; Nar, naringin group; Mes, mesalazine group; p-, phosphorylated; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; ZO-1, zona occludens-1; si, small interfering RNA; NC, negative control.
Techniques Used: Activation Assay, Western Blot, Biomarker Discovery, Knockdown, Expressing, Transfection, Small Interfering RNA, Negative Control
Related Articles
Bioprocessing:Article Title: PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p Article Snippet: PEITC was purchased from Sigma-Aldrich (Shanghai, China) and cisplatin was purchased from Solarbio (Beijing, China). .. Polyclonal antibodies against JAK2 (bs-23003R), STAT3 (bsm-33223 M), Article Title: PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p. Article Snippet: PEITC was purchased from Sigma-Aldrich (Shanghai, China) and cisplatin was purchased from Solarbio (Beijing, China). .. Polyclonal antibodies against JAK2 (bs-23003R), STAT3 (bsm-33223 M), Gel Permeation Chromatography:Article Title: Deoxycholic Acid and Lipoteichoic Acid cooperatively drive macrophage M2/M1 polarization via TGR5/STAT3 and TLR2/NF-κB to fuel HCC progression in obesity Article Snippet: .. Primary antibody concentrations were: p-NFκB p65 (ab76302, a dilution ratio of 1:1000, Abcam), p-STAT3( Saline:Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway Article Snippet: The proteins were resolved by 8–12% SDS-PAGE and transferred to immunoblot PVDF membranes (cat. no. IPVH00010; Merck KGaA). .. The membranes were blocked with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 2 h at room temperature, then incubated at 4°C overnight with primary antibodies against IL-6 (1:1,000; cat. no. Bs-0782R; BIOSS), phosphorylated (p-)JAK2 (1:1,000; cat. no. bs-2485R; BIOSS), JAK2 (1:1,000; cat. no. bs-0908R; BIOSS), Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway. Article Snippet: ulcerative colitis (uc) is a chronic autoimmune disease characterized by mucosal inflammation and disrup‐ tion of the intestinal barrier.. Current therapies often produce adverse effects, underscoring the need for novel treatment options.. Naringin, a flavonoid from Citrus aurantium l., has shown anti‐inflammatory potential in inflammatory bowel disease. Incubation:Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway Article Snippet: The proteins were resolved by 8–12% SDS-PAGE and transferred to immunoblot PVDF membranes (cat. no. IPVH00010; Merck KGaA). .. The membranes were blocked with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 2 h at room temperature, then incubated at 4°C overnight with primary antibodies against IL-6 (1:1,000; cat. no. Bs-0782R; BIOSS), phosphorylated (p-)JAK2 (1:1,000; cat. no. bs-2485R; BIOSS), JAK2 (1:1,000; cat. no. bs-0908R; BIOSS), Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway Article Snippet: .. Membranes were subsequently incubated separately with primary antibodies for p-JAK2 (1:1,000; cat. no. bs-2485R; BIOSS), JAK2 (1:1,000; cat. no. bs-0908R; BIOSS), Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway. Article Snippet: ulcerative colitis (uc) is a chronic autoimmune disease characterized by mucosal inflammation and disrup‐ tion of the intestinal barrier.. Current therapies often produce adverse effects, underscoring the need for novel treatment options.. Naringin, a flavonoid from Citrus aurantium l., has shown anti‐inflammatory potential in inflammatory bowel disease. |